Expert: OGD on track to approve more generic drugs in FY2022
Regulatory NewsJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesChemistry, Manufacturing and Controls (CMC)ComplianceNorth AmericaPharmaceuticalsQuality Assurance and ControlRegulatory Intelligence/Policy